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Abstract
The pulmonary artery catheter (PAC) was introduced in 1971 for
the assessment of heart function at the bedside. Since then it has
generated much enthusiasm and controversy regarding the
benefits and potential harms caused by this invasive form of
hemodynamic monitoring. This review discusses all clinical studies
conducted during the past 30 years, in intensive care unit settings
or  post mortem, on the impact of the PAC on outcomes and
complications resulting from the procedure. Although most of the
historical observational studies and randomized clinical trials also
looked at PAC-related complications among their end-points, we
opted to review the data under two main topics: the impact of PAC
on clinical outcomes and cost-effectiveness, and the major
complications related to the use of the PAC.
Introduction
No single monitoring device in the history of medicine has
created as much enthusiasm and controversy as has the
pulmonary artery catheter (PAC). Pulmonary artery (PA)
catheterization was first performed in the mid-1940s under
fluoroscopic guidance. With the application of distal tip
balloon floatation, introduced by Ganz in the 1960, it became
available to the bedside clinician. However, up until the early
1970s PACs were used almost exclusively for diagnostic
purposes in catheterization laboratories to identify potential
cardiac surgical cases. In 1971 Swan and colleagues [1]
introduced the first commercially available balloon-tipped
catheter that could be inserted at the bedside for assessment
of cardiac pump function. The initial studies focused on the
ability of PAC-derived data to identify patients whose natural
history was different and in whom treatments would
presumably also be different. Interestingly, no clinical trials
were initially conducted to determine whether patient
outcomes were altered by data derived from insertion of
these catheters or the associated therapeutic interventions. In
fact, PACs have been widely used in critically ill patients for
diagnosis and therapeutic guidance, just because benefit
was simply assumed. One estimate of the use of PAC
monitoring in the USA [2] showed that, as of 2000, more
than 1.2 million PACs were placed annually, with associated
costs of over US$2 billion.
This review describes the evidence on the impact and
complications of PAC use in critically ill patients. A summary
of clinical studies using PAC along with the significant
findings of each is brought in Table 1. We specifically
exclude studies focusing on use of the PAC exclusively in the
operating room, because operating room monitoring is often
used to eliminate complications arising from surgery rather
than to treat underlying conditions. Furthermore, any adverse
intraoperative outcome is considered serious, whereas many
trauma and septic shock patients often die despite
aggressive and appropriate resuscitation. However, we do
consider studies that include PAC monitoring as an overall
package of management throughout the course of critical
illness that also involves surgery.
Impact of PAC on patients outcome
Observational studies
During the 1980s two retrospective observational studies of
patients with acute coronary syndromes questioned for the
first time the benefit and safety of PAC monitoring, suggest-
ing a higher mortality in patients undergoing PAC placement.
Gore and coworkers [3] conducted a retrospective study in
3263 patients with acute myocardial infarction (MI). They
found a consistent and significant increase in PAC use in
patients with acute MI over time, from 7.2% in 1975 to
19.9% in 1984. They also found use of a PAC to be
associated with increased length of hospital stay, irrespective
of the development of acute clinical complications, without
any long-term benefit. Zion and coworkers [4] analyzed the
use of PAC in a registry including 5841 hospitalized patients
with acute MI. A total of 371 patients underwent PAC
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placement, and in-hospital mortality was found to be higher in
patients with congestive heart failure (CHF) who received a
PAC irrespective of the presence or absence of ‘pump
failure’. One may argue that PAC use is reserved for sicker
patients, thus inappropriately skewing such data against PAC
use. Further analysis supported this assumption that the PAC
was used more frequently in sicker patients. However, on
adjusting for the severity of CHF, no difference in mortality
was found in patients with mild or moderate CHF. Therefore,
Zion and coworkers concluded that although higher in-
hospital mortality was found in patients receiving PAC, this
excess was probably related to differences in severity of
CHF. They assumed that it was unlikely that PAC increased
mortality because severity-adjusted mortality rates were
similar. The issue of adjustment for severity of illness when
comparing groups recurs in later studies. Specifically, how
does one adjust for differences in case mix? Severity scores
were not calibrated to adjust for comparisons between
heterogeneous groups.
In the 1990s more investigators became interested in addres-
sing the relationship between survival and PAC use. How-
ever, those studies focused more on the potential harm of
using PACs. In 1996 Connors and coworkers [5] conducted
a retrospective observational study of patients with end-stage
terminal disease who were expected to die within 12 months
of enrollment, analyzing the subgroup of patients who
required intensive care unit (ICU) admission separately. In all,
5735 critically ill patients from a 9105 SUPPORT (Study to
Understand Prognoses and Preferences for Outcomes and
Risks of Treatments) patient cohort were retrospectively
analyzed. Of this subset, 2184 (24%) patients underwent
PAC placement; from this subgroup the investigators
identified 1008 (11%) patients for whom matched non-PAC
critical care patients were available for analysis. The data
suggested that PAC use in the critically ill was associated
with increased 30-day mortality (odds ratio [OR] 1.24),
increased costs of care (mean difference in cost US$13,600),
and increased length of ICU stay (mean difference 3 days),
even after adjusting for some of the underlying risk factors for
catheterization. Nevertheless, the matching criteria were based
on demographic parameters such as sex, age, patient
education and type of health care insurer, but not need for
catecholamines. Thus, it is not clear whether the matching of
patients was appropriate. Furthermore, as designed, the
propensity score used in that study would be insensitive to a
response to therapy within 24 hours. Thus, failure to respond to
initial therapy could be an important missing covariate in this
propensity score and could account for much of the increased
mortality and use of resources associated with PAC use.
The latter study [5] raised many questions about the safety of
PAC use, and so it is important to consider the flaws of that
work. First, patients who did not respond to initial therapy
were more likely to undergo PAC, as demonstrated by the
TISS (Therapeutic Intervention Scoring System) score
employed that study. Second, patients managed with a PAC
were more likely to enter the study with multiple organ failure,
acute respiratory failure, CHF and higher APACHE (Acute
Physiology and Chronic Health Evaluation) III score - factors
known to be associated with increased mortality. Third, the
patients receiving a PAC had lower mean arterial pressures
and baseline serum albumin concentration, which are two
other factors associated with increased mortality. Thus, it is
not clear that PAC use increased mortality, even in the
SUPPORT cohort. Although the authors were unable to
account for this apparent lack of benefit, they suggested that
a randomized controlled trial of PAC use might clarify the
result.
In 2000 another large retrospective observational study of
10,217 patients, conducted by Rapoport and coworkers [6],
identified an independent association between PAC use and
admission to a surgical ICU (a twofold increase), patient race
(OR 1.38 for white patients), care delivered by an intensivist
(a two-thirds reduction in the probability of catheter use), and
having private insurance coverage (OR 1.33). Therefore, they
suggested that studies measuring clinical and economic
outcomes could help in developing policies for rational use of
PACs. However, Murdoch and coworkers [7] conducted a
similar study to that by Connors and coworkers described
above. Considering 15 relevant variables in 4182 ICU
patients (1849 with PAC use and 2333 without), they
demonstrated a propensity score of 0.88, similar to that
reported by Connors and colleagues (0.83), indicating good
predictive value for insertion of a PAC, which was also found
to be a strong predictor of death (OR 45, 95% confidence
interval [CI] 34.7-58.3). However, use of a PAC was not
predictive of death (OR 1.08, 95% CI 0.87-1.33) after
correction for treatment bias using this propensity score. This
analysis confirms the hypothesis tested, namely that mortality
is greater for patients receiving a PAC, although the
increased mortality is not related to the PAC itself.
To underscore the concept that patients who have a higher
risk of dying are more likely to receive a PAC, Polanczyk and
coworkers [8] reported a prospective observational study of
4059 patients undergoing major elective non-cardiac surgery.
The purpose of the study was to evaluate the relationship
between use of perioperative PAC and postoperative cardiac
complication rates in patients undergoing major noncardiac
surgery. Multivariate analysis identified a threefold increase in
major postoperative cardiac events and a twofold increase in
major noncardiac events in those patients treated with a
PAC. They also suggested that randomized clinical trials
should be conducted to evaluate the impact of this
intervention on perioperative care.
Controversies over benefits of PAC: urge for clinical trials
In mid-1990, following the controversies regarding the safety
of PAC use raised by the Connors study [5], Dalen and Bone
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should impose a moratorium against use PAC until further
studies were done. This caused a series of letters to the
editors of various journals about disagreements among
critical care physicians regarding the utility of and risks
associated with PAC monitoring.
A survey of physician members of the Society of Critical Care
Medicine in the USA was then conducted to evaluate
physicians’ attitudes toward and knowledge of the PAC and
its use [10]. With a 22% return rate, the results of the survey
were significant in that 95% of the respondents felt that a
moratorium against PAC use was not warranted and that
75% of the respondents favored a prospective, randomized
controlled trial involving PAC. The survey also showed that
one-third of respondents incorrectly identified PA occlusion
pressure on a clear tracing. This inability to identify one of the
key hemodynamic variables available from PAC monitoring
correctly raised another issue, namely that of the quality of
training of ICU specialists in interpreting PAC findings.
Subsequently, other studies were done to evaluate whether
ICU physicians could predict the hemodynamic values
generated by PAC monitoring prior to performing the
procedure. If they could, then it was reasoned that they did
not need to perform PAC placement. These small series
studies found an average 50% rate of correct prediction of
PAC values by physicians. Furthermore, 50% of PAC-derived
variables in critically ill patients led to a change in
management. Importantly, these changes tended to
congregate among those patients with circulatory shock who
were unresponsive to standard therapeutic measures [11-13].
Interestingly, these were the very patients originally
suggested by Swan and coworkers [1] to be those who
would benefit from PAC placement.
Other studies [14,15] compared the utility of PAC and CVP-
only monitoring in managing the perioperative period in
patients undergoing cardiac and vascular surgery. No
differences in clinically relevant outcomes were seen
between the two groups (including a specific subgroup
analysis of the highest risk patients); these outcomes
included length of ICU stay, occurrence of perioperative
cardiac, pulmonary or renal morbidities, in-hospital mortality,
major hemodynamic aberrations, and significant noncardiac
systemic complications. The one statistically significant
difference between groups was the professional fee charged
for anesthetic care, which was higher for patients with PAC
than for those with CVP catheters. These studies, along with
other limited cost-effectiveness studies [2,16], suggested
that there was a need for large multicenter randomized
clinical trials and recommended that, until then, even high-risk
cardiac and vascular surgical patients may safely be
managed without routine PAC placement, which could result
in important cost savings.
These controversies stimulated a series of small clinical trials;
unfortunately, the discrepant results of those studies only
exacerbated the uncertainty. Guyatt [17] reported a
significant difference in favor of patients not receiving PAC,
but Sandham and coworkers [18] found no benefit from
therapy directed by PAC over standard care in high-risk
surgical patients. At the same time, in an evaluation of all
randomized clinical trials of PACs using a random effect
model, Ivanov and coworkers [19] reported a relative risk ratio
of 0.8 in favor of PAC, but they also showed serious
deficiencies, including a lack of a priori sample size
calculations, unclear definitions of concomitant therapy,
inability to blind physicians and patients, and lack of blinded
outcome assessments. Therefore, all of these studies
collectively suggested that better designs and large,
multicenter randomized clinical trials were needed.
Multicenter clinical trials
In 2003, Richard and coworkers [20] conducted a multi-
center randomized clinical trial of early use of PAC versus no
PAC in management of patients with shock, acute respiratory
distress syndrome, or both. The treatment was left to the
discretion of treating physicians. As with all previous
prospective studies, those investigators found no significant
impact of PAC on mortality (at 28 or 90 days) or morbidity
(organ failure or ventilator dependence). Valentine [21] and
Bender [22] and their groups independently found similar
results in vascular surgery patients; they concluded that
routine use of PACs for perioperative monitoring during aortic
surgery is not beneficial and may even be associated with a
higher rate of intraoperative complications.
Recently, the UK National Health Service sponsored study
PAC-Man (Pulmonary Artery Catheters in Patient Manage-
ment in Intensive Care) [23] reported results comparing
PAC-based versus CVP-based management. As with all
previous studies, the PAC-Man study found no difference in
hospital mortality between patients managed with and those
managed without a PAC. It also found that none of the
complications associated with insertion of a PAC (<10%)
was fatal. Therefore, no clear evidence of benefit or harm
from managing critically ill patients with a PAC was found.
Finally, data from the ESCAPE (Evaluation Study of
Congestive heart failure and Pulmonary artery catheter
Effectiveness) trial [24] were recently published. In that trial it
was found that basing the decision to administer vasodilator
and diuretic therapy on PAC data plus clinical judgment was
not superior to basing the decision on clinical judgment
alone, in terms of decreasing mortality or length of hospital
stay. The time to resolution of symptoms was faster with PAC
data plus clinical judgment, but this did not translate into
other tangible benefits. The authors did note that there was a
trend toward better outcomes using PAC-guided therapy in
centers admitting greater numbers of patients, and there was
a consistent trend toward greater functional improvement
following PAC-guided therapy, which could reflect the close
relation between filling pressures and symptoms of CHF. That
Available online http://ccforum.com/content/10/S3/S8both ESCAPE and PAC-Man found PAC to be safe suggests
that previous retrospective reports of excess mortality with
this monitoring device were confounded by the severity of the
clinical settings in which the PAC was applied [5,23,24].
Use of PAC to guide treatment protocol
Based on the results of these retrospective and prospective
clinical trials, there is level 1 evidence that nonspecific use of
the PAC in the general management of critically ill patients is
not associated with any change in mortality or morbidity. To a
certain extent, these findings are comforting because they
demonstrate that critical care physicians can use a highly
invasive catheter with a series of potential complications
(infra vide) without causing harm. However, these data do not
address the fundamental issue regarding the utility of the
PAC in patient management. Every study reported above
merely compared the presence of a PAC with its absence.
None of the studies used PAC-specific data to drive a
treatment protocol that is known to improve outcome.
Presently, results with numerous resuscitation algorithm
protocols have reflected a consistent theme of benefit or
harm, depending on the timing and aggressiveness of that
resuscitation. Resuscitation in shock can be divided into
primary and secondary periods. The primary period is the time
from initial evaluation through to the first round of resuscita-
tion. The goals during this period are cardiopulmonary/
cerebral resuscitation [25]. This encompasses establishment
of an adequate airway and, if necessary, mechanical
ventilation, restoration of productive cardiac rhythm and
forward blood flow, and attainment of a mean arterial blood
pressure above 60 mmHg [26]. Without achieving the latter
initial goal, all other resuscitative goals are of questionable
value and thus should not be considered alone. Once mean
arterial blood pressure is sufficient to maintain cerebral and
myocardial perfusion, then the secondary period of
resuscitation begins. The goals during this period are
establishment of an adequate organ perfusion pressure for all
organs, establishment of adequate organ blood flow, and
establishment of adequate oxygen transport to metabolically
active tissues. The first two goals are achieved by utilizing
volume expansion and vasoactive agents, often using data
acquired by invasive hemodynamic monitoring via a PAC. The
utility of the PAC must be assessed within this context,
because no monitoring device can be expected to improve
patient outcome if it is not coupled to a treatment that itself
improves outcome.
In support of this is the recent, large, single-center clinical
trial of early goal-directed therapy for the management of
severe sepsis [27]. That study documented markedly
improved outcomes when individuals were aggressively
treated for circulatory shock in the emergency department
during the initial 6 hours of hospitalization, rather than waiting
for them to be transferred to the ICU for better monitoring.
That study focused on rapidly achieving an adequate mean
arterial pressure, CVP and urine output, as well as an
adequate degree of tissue perfusion, as assessed by superior
vena caval oxygen saturation. This study is in stark contrast to
the negative findings of numerous large studies that aimed to
improve survival in patients once they were transferred to the
ICU using similar resuscitation end-points [28-31]. These
negative studies do not mean that resuscitation is ineffective
in supporting life in patients who are in shock. They merely
demonstrate that there is no specific level of oxygen transport
or mixed venous oxygen saturation that one must attain to
ensure a good outcome once shock has induced tissue
injury. Thus, the lack of documented benefit of PAC use in
these clinical trials probably more reflects inadequate study
design than inadequate utility [32].
Shoemaker and coworkers [33] conducted a prospective trial
of supranormal oxygen delivery values in high-risk surgical
patients before surgery and then during the operative interval.
They then followed these patients during the postoperative
period for development of acute lung injury, length of time of
mechanical ventilation, mortality and total hospital costs.
Following initial resuscitation (blood pressure >120/80 mmHg,
hematocrit >34), patients were assigned to one of three
treatment groups: PA control group (n = 30; goals: cardiac
index [CI] 2.8-3.5 ml/min per m2, global oxygen transport
[TO2] 400-550 ml/min per m2, and oxygen consumption [VO2]
120-140 ml/min); PA protocol group (n = 28; goals: CI
>4.5 ml/min per m2, TO2 >600 ml/min per m2, and VO2
>170 ml/min); and CVP control group (no specific additional
treatment goals). In each group the targeted levels of CI, TO2,
and VO2 were achieved. The PA protocol group, as compared
with the PA control group, had less time on the ventilator (2.3
versus 9.4 days), fewer postoperative deaths (1/28 versus
10/30), and fewer ICU days (10.2 days versus 15.8 days).
Similarly, their hospital costs were the lowest of the three
groups. The CVP group fared similarly to the PA control
group. These data are in accordance with the large clinical
trials reviewed above. When a PAC is present but not used
to drive therapy, outcomes are no different than if the PAC is
not present.
Interestingly, Lobo and coworkers [34] examined maximizing
oxygen delivery in high-risk elderly surgical patients. They
included 37 high-risk patients aged above 60 years. They
compared a control resuscitation (n = 18; TO2 520-600 ml/min
per m2) versus a hyper-resuscitation protocol (n = 19; TO2
>600 ml/min per m2). They observed that the TO2 goals were
achieved in only 13 out of 37 patients (achievers). Impor-
tantly, there were more postoperative complications in the
control group, including infections (12/18 in the control
group versus 6/19 in the protocol group; relative risk [RR]
0.47, 95% CI 0.2-0.9) and cardiovascular dysfunction (RR
0.34, 95% CI 0.1-0.8). A mortality benefit was suggested but
not demonstrated (mortality at 28 days: 33% in the control
group versus 16% in the protocol group; RR 0.32, 95% CI
0.1-0.98). Importantly, these benefits also observed in the
Critical Care    Vol 10 Suppl 3 Hadian and Pinsky
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that hyper-resuscitation prior to insult improves outcomes
even if it does not increase the measured oxygen delivery.
Gattinoni and coworkers [29] studied 762 patients from 56
centers, all of whom had an Acute Physiology Score above
11. The population included patients undergoing high-risk
surgery; those with massive blood loss, sepsis and
respiratory failure; and trauma patients. However, the mean
time from developing severe shock to enrollment in the study
was 23 hours, making this study a late recovery protocol, not
an early resuscitation protocol. The goals of therapy were
separated into three treatment groups: CI 2.5-3.5 ml/min
per m2; CI >4.5 ml/min per m2; and mixed venous oxygen
saturation >70%. Unfortunately, the therapeutic goals were
achieved in less than half of the second group. Importantly,
the investigators found no difference in ICU or 6-month
mortality for any diagnosis, even in the subgroup of patients
in whom the targeted goals were achieved. This study
concluded that therapy aimed at achieving supranormal CI or
normal mixed venous oxygen saturation in patients with
severe circulatory shock for more than 24 hours cannot be
justified. In support of this lack of benefit, Hayes and
coworkers [28] studied 100 critically ill patients with severe
circulatory shock, assigning them to either aggressive
supranormal oxygen delivery levels or normal oxygen delivery
levels. They found markedly increased mortality in the
treatment group compared with the control group (54%
versus 34%; P < 0.05). Thus, aggressive therapy once tissue
injury has occurred will not restore organ function but will
carry its own increased risks. However, one can also
conclude that early aggressive resuscitation before organ
injury may be beneficial in high-risk patients, but is probably
of marginal benefit in those who are less sick.
Recently, Shah and coworkers [35] conducted a meta-
analysis of 5051 patients studied in 13 RCTs during the past
20 years, randomized to the use of PAC or no PAC. They
found that there was a significantly higher rate of use of
vasodilator and inotropic agents in PAC groups, but there
was no difference in mortality between groups. The use of
PAC did not improve survival or decrease the length of
hospital stay. Importantly, none of the studies used PAC-
derived variables to drive therapies of proven benefit. They
merely noted the impact of having a PAC in place on
outcome. They stated, as others have, that monitoring without
linkage to therapies of proven benefit is unlikely to show
benefit. All of these trials excluded patients in whom treating
physicians thought a PAC was required for treatment, and so
it is possible that patients outside the studied population –
such as patients who are evaluated for heart and lung
transplants – are in fact those who would benefit from PAC
placement [35].
The NIH ARDSNet FACTT (Fluids and Catheters Treatment
Trial) study, a multicenter clinical trial of PAC versus CVP,
has just finished enrollment. It is study of 2 × 2 factorial
design comparing liberal versus conservative fluid manage-
ment with specific hemodynamic goals and treatment
strategies, which involve use of fluids, inotropes, vaso-
pressors, and diuretics as per protocols. This study is the
only trial coupling a treatment protocol with use of PAC.
Therefore, if it identifies any difference in outcomes between
patients managed by PAC and those managed by CVP, then
one can conclude that protocolized treatment guided by PAC
is more or less effective, and so the study has more credibility
and may justify a change to practice regarding use of PAC in
the ICU. However, FACTT used PAC-derived filling pressures
not to guide resuscitation but to limit it, considering the issue
of whether limited resuscitation to avoid increasing pulmonary
edema in acute respiratory distress syndrome can improve
outcome. Thus, the results of this trial, although important, will
not address the broader issue of PAC-guided therapy in the
critically ill.
Summary: impact of PAC on outcome
The combined literature shows that the nonspecific
placement of a PAC in a critically ill patient does not impair
outcomes. However, no study has used PAC-derived
variables to drive treatment protocols of proven benefit to
determine whether PAC-specific data result in better
outcomes than do data derived from less invasive devices,
such as the central venous catheter and echocardiography.
Such studies are needed, not only to validate use of the PAC
or reject it, but also to validate or reject the use of any
hemodynamic monitoring tool.
Complications
Pulmonary arterial catheterization is an invasive procedure. It
requires the insertion of a central venous port and passage of
a catheter across two heart values. Inflation of the catheter
once in a PA may cause rupture of that vessel with disastrous
consequences. Furthermore, the continual presence of a
PAC increases the likelihood of catheter-related bloodstream
infections and endocarditis.
The recently published PAC-Man [23] and ESCAPE [24]
randomized clinical trials identified incidences of complica-
tions of 10% and 5%, respectively, in patients in whom PAC
insertion was attempted. The most common complications in
PAC-Man were site hematoma (4%), arterial puncture (3%),
and arrhythmias needing treatment (3% with one cardiac
arrest). In ESCAPE PAC-related infections occurred in 2.5%,
catheter knotting and pulmonary infarction/hemorrhage in 1%
each, and ventricular arrhythmia in 0.5%. None of the
complications in either study led to death.
Boyd and coworkers [36] reported on 528 PAC insertions in
500 consecutive patients at the New York University Medical
Center in the 1990s. They found that complications occurred
in 126 out of 528 catheterizations. Serious complications
occurred in only 23 of these 528 catheterizations (4.4%).
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.These complications, although serious, did not contribute
directly to any of the 31 deaths seen in these patients. PAC
was reported by clinicians to have been of benefit in the
management of 80% of the patients. The authors concluded
that use of PAC is justified if it is likely that the catheter will
contribute significantly to the management of the individual
patient.
In a series of 141 consecutive autopsy cases in which a
central catheter was present at the time of death [37], three
deaths were attributable to catheter use and two to
perforation. Furthermore, mural thrombi were present in 33
(33%) of 99 patients with PAC and in 12 (29%) of 42
patients with central venous catheters. The incidences of
pulmonary emboli and bacteremia were no greater in patients
with thrombi than in those without. The use of central
catheters may thus be complicated by perforation or develop-
ment of mural thrombi. Although the thrombi may embolize or
may become infected, the incidence and clinical significance
appear to be low. Importantly, complications of central
vascular access define the primary complications of PAC,
and thus are not diminished if the patient only has a central
venous catheter placed.
In the following discussion we review studies that look into
PAC-related complications and divide them into three major
categories.
Catheter-related infections and thromboembolic events
Elliott and coworkers [38] evaluated the incidence and the
significance of complications resulting from the use of PAC
to monitor critically ill patients in a prospective study of 116
PAC insertions. In two cases (1.7%) staphylococcal
bacteremia probably originated from the catheter. In addition,
the PAC led to two cases (1.7%) of subclavian vein
thrombosis. Post mortem examinations revealed perforations
of the pulmonic valve in one case. Furthermore, in a retro-
spective analysis of 630 PAC placements in 184 patients
with aneurysmal subarachnoid hemorrhage, Rosenwasser
and coworkers [39] demonstrated a 13% incidence of
catheter-related sepsis, a 2% incidence of congestive heart
failure, and a 1.3% incidence of subclavian vein thrombosis.
Sise and colleagues [40] reported similar findings. They
prospectively studied the use of 320 catheters in 219
critically ill patients. Major complications (including six
pneumothoraces and three arrhythmias requiring treatment,
one of which was fatal) occurred in 3% of catheterizations,
but only one subclavian vein thrombosis occurred. Site
complications occurred more frequently in catheters
maintained for longer than 72 hours.
Pace and coworkers [41] reported on an autopsy series of
413 patients over 2 years assessing the incidence of aseptic
thrombotic endocardial vegetations (TEVs) after PAC use.
They found five instances of aseptic TEV, three of which
occurred in 88 patients with PACs, one in 120 patients with
central venous catheters, and one in the 205 patients without
central vascular catheters. They concluded that the incidence
of TEV is increased by PAC placement. The impact of TEV on
patient mortality, unfortunately, could not be ascertained.
Lange and coworkers [42] examined 36 hearts of patients
who died with an indwelling PAC in place to assess the
incidence and extent of localized lesions in the right side of
the heart. Bland mural thrombosis in the superior vena cava,
the right atrium, and the PA was found in 22 out of 36 cases
(61%). Patients with catheter placement durations in excess
of 2 days had a greater incidence and extent of bland mural
thrombosis (79%) than did patients with short-term
catheterization (41%; P < 0.01). Anticoagulation had no
influence on bland mural thrombosis. Valvular hemorrhage
occurred in 31% and TEV in 8% of the hearts. No case of
infective endocarditis was identified. Four of 36 cases (11%)
had evidence of pulmonary infarction that appeared to be
unrelated to the lesions in the right side of the heart.
Endocardial lesions were common complications of PAC but
had no significant impact on clinical courses.
Mermel and coworkers [43] conducted a prospective clinical
study of hospitalized adult medical and surgical patients
undergoing PAC placement. Overall, 65 (22%) of 297 PACs
exhibited local infection of the introducer (58 catheters) or
the intravascular portion of the PAC (20 catheters); only two
catheters (0.7%) caused bacteremia. Eighty per cent of
infected PACs (the introducer or PAC) exhibited
concordance with organisms cultured from skin of the
insertion site, 17% with a contaminated hub, and 18% with
organisms contaminating the extravascular PAC portion
beneath the sleeve. Isolates from infected PACs were most
likely to exhibit concordance with concomitantly infected
introducers (71%). The risk for PAC-associated bacteremic
infection with good sterile technique was about 1%.
However, with heavy colonization of the insertion site,
percutaneous insertion in the internal jugular vein rather than
subclavian vein, catheterization for longer than 3 days, and
insertion with less stringent barrier precautions significantly
increased the risk for catheter-related infection.
In another case series study of 32 patients brought to
autopsy with a right PAC in place, Connors and coworkers
[44] identified thrombosis in 53% and intimal fibrin deposition
in 66%. Ninety per cent of cases had either thrombosis or
hemorrhage, or both, in this autopsy series, and the incidence
of thrombosis was significantly higher if the catheter was in
place for longer than 36 hours.
Pulmonary artery rupture and endocardial damage
Kearney and Shabot [45] conducted a retrospective chart
review study of 32,442 inpatients requiring PAC monitoring
in the operating rooms and ICUs of a large, private teaching
hospital over a 17-year period. Ten patients suffered PA
rupture (observed rupture rate 0.031%), seven of whom died
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(page number not for citation purposes)(70% mortality rate). All 20 patients had hemoptysis and five
(50%) had pulmonary hypertension. Two patients (20%) had
undergone anticoagulation at the time of rupture. Four of the
six surgical patients were still in surgery at the first sign of
rupture. Patients who underwent thoracotomy for PA rupture
showed better survival than who did not.
Rowley and coworkers [46] studied the frequency and
clinical importance of right-sided endocardial lesions in
patients who received a PAC within 1 month of death. Of the
55 catheterized patients, 53% had one or more right-sided
endocardial lesions; 22% had subendocardial hemorrhage,
20% sterile thrombus, 4% hemorrhage and thrombus, and
7% infective endocarditis. Fifty-six per cent of lesions were
located on the pulmonic valve, 15% on the tricuspid valve,
15% in the right atrium, 10% in the right ventricle, and 5% in
the main PA. All four patients with infective endocarditis had
had positive ante mortem blood cultures while the catheter
was in place, but in only one had the diagnosis of
endocarditis been suspected clinically. The unusual locations
of the infected vegetations (on the pulmonic valve in three
and in the right atrium in one) and the similar location of the
uninfected lesions suggest that the infective endocarditis was
a consequence of catheter-induced endocardial damage with
concurrent or subsequent bacteremia. Among the 87 non-
catheterized patients, there were two subendocardial
hemorrhages and one resolving right atrial thrombus. These
authors concluded that endocardial damage from the PAC is
common and that right-sided infective endocarditis should be
suspected in all bacteremic catheterized patients.
Arrhythmias
Sprung and coworkers [47] tried to determine the incidence
of new right bundle branch block (RBBB) and complete heart
block during PAC insertion. They studied 293 patients
undergoing 307 PAC insertions. They found that 3% were
associated with the development of a new RBBB. None of
the 14 patients with a pre-existing left bundle branch block
(LBBB) developed complete heart block. The incidence of
complete heart block during PA catheterization of patients
with previous LBBB was not higher than the incidence of
RBBB in patients without underlying conduction defects.
Elliot and coworkers [38] found a 77% incidence rate of
arrhythmias, including premature atrial or ventricular
depolarizations, ventricular tachycardia, and transient RBBB
in 116 patients undergoing PAC insertion, but this high rate
was not associated with morbidity or mortality.
In another study, Iberti and colleagues [48] reported
advanced ventricular arrhythmias (three or more consecutive
premature ventricular contractions) in 25–68% of ICU
patients undergoing PA catheterization. A group of 56 ICU
patients who received a PAC were prospectively studied to
determine the incidence of catheter-induced arrhythmias and
the time required for catheterization. Advanced ventricular
arrhythmias were observed in seven out of 56 (12.5%)
patients, the longest duration of arrhythmia being seven
consecutive premature ventricular contractions. No patient
required treatment for their arrhythmias and all arrhythmias
resolved with catheter movement. There was no statistical
difference in catheterization times or incidence of arrhythmias
between critically ill patients and preoperative patients.
Sprung and coworkers [49] revisited this issue by studying
60 sequential PAC insertions. Twenty-nine out of 60
catheterizations (48%) were associated with premature
ventricular contractions and 20 (33%) were associated with
ventricular tachycardia. Two patients required antiarrhythmic
therapy or a precordial thump to convert ventricular tachy-
cardia. One patient developed ventricular tachycardia and
fibrillation and died. Based on these data the incidence of
serious PAC-associated arrhythmias is very low and appears
not to influence patient outcome.
Conclusion
One may conclude that PAC use is associated with
increased risk for arrhythmias during insertion, infections and
thrombotic complications during prolonged retention
(>48 hours), and very rare PA rupture. Considering that the
there are no benefits of PAC use that is not associated with a
defined treatment protocol, this review supports the discon-
tinuance of routine PAC insertion unless it is coupled to a
defined treatment protocol of proven efficacy. Such protocols
exist but they need to be followed in defined high-risk patient
populations. Considering the dearth of actual clinical trials of
the utility of PAC-derived data in driving effective treatment
protocols other than those of pre-optimization, it is clear that
appropriate prospective clinical trials of proven treatments
using PAC-derived data are indicated if the PAC is to retain
its place in monitoring critically ill patients.
Competing interests
MH declares no competing interests. MRP has received
financial benefits from Arrow International, Edwards
Lifesciences and LiDCO Ltd and holds shares in LiDCO Ltd.
MRP holds US Patent 6.776.764 and has received NIH
Grants HL67181, HL07820 and HL073190.
Acknowledgement
This work was supported in part by NIH grants HL67181 and
HL07820.
References
1. Swan HJC, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D:
Catheterization of the heart in man with use of a flow-directed
balloon-tipped catheter. N Engl J Med 1970, 283:447-451.
2. Dalen JR: The pulmonary artery catheter: friend, foe, or accom-
plice? JAMA 2001, 286:348-350.
3. Gore JM, Goldberg RJ, Spodick DH, Alpert JS, Dalen JE: A com-
munity-wide assessment of the use of pulmonary artery
catheters in patients with acute myocardial infarction. Chest
1987, 92:721-727.
4. Zion MM, Balkin J, Rosenmann D, Goldbourt U, Reicher-Reiss H,
Kaplinsky E, Behar S: Use of pulmonary artery catheters in
patients with acute myocardial infarction. Chest 1990,  98:
1331-1335.
Available online http://ccforum.com/content/10/S3/S8
Page 9 of 11
(page number not for citation purposes)5. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr,
Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, et al.; for
the SUPPORT Investigators: The effectiveness of right heart
catheterization in the initial care of critically ill patients. JAMA
1996, 276:889-897.
6. Rapoport J, Teres D, Steingrub J, Higgins T, McGee W,
Lemeshow S: Patient characteristics and ICU organizational
factors that influence frequency of pulmonary artery catheteri-
zation. JAMA 2000, 283:2559-2567.
7. Murdoch SD Cohen AT, Bellamy MC: Pulmonary artery
catheterization and mortality in critically il patients. Br J
Anaest 2000, 85:611-615.
8. Polanczyk CA, Rohde LE, Goldman L, Cook EF, Thomas EJ, Mar-
cantonio ER, Mangione CM, Lee TH: Right heart catheterization
and cardiac complications in patients undergoing noncardiac
surgery: an observational study. JAMA 2001, 286:309-314.
9. Dalen JE, Bone RA: Is it time to pull the pulmonary artery
catheter. JAMA 1996, 276:916-918.
10. Trottier SJ, Taylor RW: Physicians’ attitudes toward and knowl-
edge of the pulmonary artery catheter: Society of Critical Care
Medicine membership survey. New Horiz 1997, 5:201-206.
11. Staudinger T, Locker GJ, Laczika K, Knapp S, Burgmann H,
Wagner A, Weiss K, Zimmerl M, Stoiser B, Frass M: Diagnostic
validity of pulmonary artery catheterization for residents at an
intensive care unit. J Trauma 1998, 44:902-906.
12. Mimoz O, Rauss A, Rekik N, Brun-Buisson C, Lemaire F, Brochard
L: Pulmonary artery catheterization in critically ill patients: a
prospective analysis of outcome changes associated with
catheter-prompted changes in therapy. Crit Care Med 1994,
22:573-579.
13. Steingrub JS, Celoria G, Vickers-Lahti M, Teres D, Bria W: Thera-
peutic impact of pulmonary artery catheterization in a
medical/surgical ICU. Chest 1991, 99:1451-1455.
14. Tuman KJ, McCarthy RJ, Spiess BD, DaValle M, Hompland SJ,
Dabir R, Ivankovich AD: Effect of pulmonary artery catheteriza-
tion on outcome in patients undergoing coronary artery
surgery. Anesthesiology 1989, 70:199-206.
15. Isaacson IJ, Lowdon JD, Berry AJ, Smith RB 3rd, Knos GB, Weitz
FI, Ryan K: The value of pulmonary artery and central venous
monitoring in patients undergoing abdominal aortic recon-
structive surgery: a comparative study of two selected, ran-
domized groups. J Vasc Surg 1990, 12:754-760.
16. Smith KJ, Pesce RR: Pulmonary artery catheterization in exac-
erbations of COPD requiring mechanical ventilation: a cost-
effectiveness analysis. Respir Care 1994, 39:961-967.
17. Guyatt G: A randomized controlled trial of right-heart
catheterization in critically ill patients. Ontario Intensive Care
Study Group. J Intensive Care Med 1991, 6:91-95.
18. Sandham JD, Hull R, Brant RF, Knox L, Pineo GF, Doig CJ,
Laporta DP, Viner S, Passerini L, Devitt H, et al.; for the Canadian
Critical Care Clinical Trials Group: A randomized, controlled
trial of the use of pulmonary-artery catheters in high-risk sur-
gical patients. N Engl J Med 2003, 348:5-14.
19. Ivanov RI, Allen J, Sandham JD, Calvin JE: Pulmonary artery
catheterization: a narrative and systematic critique of random-
ized controlled trials and recommendations for the future.
New Horiz 1997, 5:268-276.
20. Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud
D, Boulain T, Lefort Y, Fartoukh M, Baud F, et al.; French Pul-
monary Artery Catheter Study Group: Early use of the pul-
monary artery catheter and outcomes in patients with shock
and acute respiratory distress syndrome. JAMA 2003,  290:
2713-2720.
21. Valentine RJ, Duke ML, Inman MH, Grayburn PA, Hagino RT,
Kakish HB, Clagett GP: Effectiveness of pulmonary artery
catheters in aortic surgery: a randomized trial. J Vasc Surg
1998, 27:203-212.
22. Bender JS, Smith-Meek MA, Jones CE: Routine pulmonary
artery catheterization does not reduce morbidity and mortality
of elective vascular surgery: results of a prospective, random-
ized trial. Ann Surg 1997, 226:229-237.
23. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne
D, Brampton W, Williams D, Young D, Rowan K; PAC-Man study
collaboration: Assessment of the clinical effectiveness of pul-
monary artery catheters in management of patients in inten-
sive care (PAC-Man): a randomised controlled trial. The Lancet
2005, 366:435-436.
24. Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR,
Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW;
ESCAPE Investigators and ESCAPE Study Coordinators: Evalua-
tion study of congestive heart failure and pulmonary artery
catheterization effectiveness. JAMA 2005, 294:1625-1633.
25. Safar P: Cerebral resuscitation after cardiac arrest: research
initiatives and future directions. Ann Emerg Med 1993, 22:324-
349.
26. Fazekas JF, Kleh J, Parrish AE: The influence of shock on cere-
bral hemodynamics and metabolism. Am J Med Sci 1955, 229:
41-45.
27. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B,
Peterson E, Tomlanovich E: Early goal-directed therapy in the
treatment of severe sepsis and septic shock. N Engl J Med
2001, 345:1368-1377.
28. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hindo CJ, Watson
D: Evaluation of systemic oxygen delivery in the treatment of
the critically ill. N Engl J Med 1994, 330:1717-1722.
29. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A,
Fumagalli R: A trial of goal-oriented hemodynamic therapy in
critically ill patients. N Engl J Med 1995, 333:1025-1032.
30. McKinley BA, Kozar RA, Cocanour CS, Valdiva A, Sailors RM,
Ware DN, Moore FA: Normal versus supranormal oxygen
delivery goals in shock resuscitation: The response is the
same. J Trauma 2002, 53:825-832.
31. Velmahos GC, Demetriades D, Shoemaker WC, Chan LS, Tat-
evossian R, Wo CCJ, Vassiliu P, Cornwell III EE, Murray JA, Roth
B, et al.: Endpoints of resuscitation of critically injured patients:
normal or supranormal? A prospective randomized trial. Ann
Surg 2000, 232:409-418.
32. Pinsky MR, Vincent JL: Let us use the pulmonary artery
catheter correctly and only when we need it. Crit Care Med 32
2005, 33:1119-1122.
33. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS:
Prospective trial of supranormal values of survivors as thera-
peutic goals in high-risk surgical patients. Chest 1988,  94:
1176-1186.
34. Lobo SM, Salgado PF, Castillo VG, Borim AA, Polachini CA,
Palchetti JC, Brienzi SL, de Oliveira GG: Maximizing O2 delivery
in high-risk elderly surgery patients improves survivorship
without altering O2 consumption. Crit Care Med 2000,
28:3396-3404.
35. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor
CM, Sopko G, Califf RM: Impact of the pulmonary artery
catheter in critically ill patients. JAMA 2005, 294:1664-1670.
36. Boyd KD, Thomas SJ, Gold J, Boyd AD: A prospective study of
complications of pulmonary artery catheterizations in 500
consecutive patients. Chest 1983, 84:245-249.
37. Ducatman BS, McMichan JC, Edwards WD: Catheter-induced
lesions of the right side of the heart. A one-year prospective
study of 141 autopsies. JAMA 1985, 253:791-795.
38. Elliott CG, Zimmerman GA, Clemmer TP: Complications of pul-
monary artery catheterization in the care of critically ill
patients. A prospective study. Chest 1979, 76:647-652.
39. Rosenwasser RH, Jallo JI, Getch CC, Liebman KE: Complications
of Swan-Ganz catheterization for hemodynamic monitoring in
patients with subarachnoid hemorrhage. Neurosurgery 1995,
37:872-876.
40. Sise MJ, Hollingsworth P, Brimm JE, Peters RM, Virgilio RW,
Shackford SR: Complications of the flow-directed pulmonary
artery catheter: a prospective analysis in 219 patients. Crit
Care Med 1981, 9:315-318.
41. Pace NL, Horton W: Indwelling pulmonary artery catheters.
Their relationship to aseptic thrombotic endocardial vegeta-
tions. JAMA 1975, 233:893-894.
42. Lange HW, Galliani CA, Edwards JE: Local complications asso-
ciated with indwelling Swan-Ganz catheters: autopsy study of
36 cases. Am J Cardiol 1983, 52:1108-1111.
43. Mermel LA, McCormick RD, Springman SR, Maki DG: The patho-
genesis and epidemiology of catheter-related infection with
pulmonary artery Swan-Ganz catheters: a prospective study
utilizing molecular subtyping. Am J Med 1991, 91:197S-205S.
44. Connors AF, Castele RJ, Farhat NZ, Tomashefski JF: Complica-
tions of right heart catheterization: a prospective autopsy
study. Chest 1985, 88:567-572.
45. Kearney TJ, Shabot MM: Pulmonary artery rupture associated
with the Swan-Ganz catheter. Chest 1995, 108:1349-1352.
Critical Care    Vol 10 Suppl 3 Hadian and Pinsky
Page 10 of 11
(page number not for citation purposes)46. Rowley KM, Clubb KS, Smith GJ, Cabin HS: Right-sided infec-
tive endocarditis as a consequence of flow-directed pul-
monary-artery catheterization. A clinicopathological study of
55 autopsied patients. N Engl J Med 1984, 311:1152-1156.
47. Sprung CL, Elser B, Schein RM, Marcial EH, Schrager BR: Risk
of right bundle-branch block and complete heart block during
pulmonary artery catheterization. Crit Care Med 1989, 17:1-3.
48. Iberti TJ, Benjamin E, Gruppi L, Raskin JM: Ventricular arrhyth-
mias during pulmonary artery catheterization in the intensive
care unit. Prospective study. Am J Med 1985, 78:451-454.
49. Sprung CL, Jacobs LJ, Caralis PV, Karpf M: Ventricular arrhyth-
mias during Swan-Ganz catheterization of the critically ill.
Chest 1981, 79:413-415.
Available online http://ccforum.com/content/10/S3/S8
Page 11 of 11
(page number not for citation purposes)